SCHEMBL3098048

SCHEMBL3098048

COC(=O)C(C(=O)c1ccc(C)cc1)c1ccc(OC)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.52
NPC1 O15118 4/20 0.51
RAB9A P51151 3/20 0.51
TDP1 Q9NUW8 2/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 4/20 0.47
LMNA P02545 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
ACHE P22303 1/20 0.46
UTS2R Q9UKP6 2/20 0.45
CYP1A2 P05177 1/20 0.45
MAPT P10636 2/20 0.44
PAX8 Q06710 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15665536 0.94 CA1 (0.52) NPSR1NPC1RAB9AMEN1KMT2A
SCHEMBL13228062 0.91 TDP1 (0.50) NPSR1NPC1RAB9ATDP1MEN1
SCHEMBL28776229 0.88 RAB9A (0.55) NPSR1NPC1RAB9AMEN1KMT2A
SCHEMBL3094287 0.87 HPGD (0.57) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3093681 0.85 KMT2A (0.49) NPSR1NPC1RAB9AMEN1KMT2A
SCHEMBL13228059 0.84 KMT2A (0.51) NPSR1NPC1RAB9ATDP1MEN1
SCHEMBL3089257 0.84 MAPT (0.60) NPSR1NPC1RAB9ATDP1MEN1
SCHEMBL7385100 0.84 SMN1; SMN2 (0.53) NPSR1NPC1RAB9ATDP1MEN1
SCHEMBL5215589 0.84 CES2 (0.57) NPSR1NPC1RAB9AMEN1KMT2A
SCHEMBL388412 0.83 RAB9A (0.46) NPSR1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803956-B2 Benzofuran derivatives useful for treating hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2010-09-28 US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
US-20090292014-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS ZHANG CHENGZHI 2009-11-26 US disclosed
CN-101454299-A Ureide derivative and use thereof for medical purposes TORAY INDUSTRIES (JP) 2009-06-10 CN disclosed
EP-2009006-A1 UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES TORAY INDUSTRIES, INC. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292014-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS PCNA, MKI67, CDK4 NPSR1 4234/4885NPC1 1817/4885RAB9A 4187/4885
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF UROD, UTS2R, SLC14A1 NPSR1 153/4885NPC1 1768/4885RAB9A 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.